|BioReference Announces 2012 Annual Meeting Date|
ELMWOOD PARK, N.J.--(BUSINESS WIRE)--Feb. 8, 2012--
Bio-Reference Laboratories, Inc. (“BioReference”) (NASDAQ: BRLI)
announced today that it will hold its 2012 annual meeting of
stockholders (the “Annual Meeting”) on July 12, 2012. The time and
location of the Annual Meeting will be as set forth in BioReference’s
annual proxy statement for the Annual Meeting. The record date for
determining the holders of the Company's common stock entitled to vote
at the Annual Meeting will be as set forth in BioReference’s annual
proxy statement for the Annual Meeting. Stockholders wishing to submit
proposals for inclusion in the proxy statement for the Annual Meeting
must submit such proposals so as to be received by BioReference at 481
Edward H. Ross Drive, Elmwood Park, New Jersey 07407 on or before March
1, 2012. Any stockholder proposal submitted for the Annual Meeting must
relate to matters appropriate for stockholder action and otherwise
comply with the rules and regulations of the Securities and Exchange
Commission (including Rule 14a-8 of the Securities Exchange Act of 1934,
as amended) relating to stockholders' proposals.
BioReference is a clinical testing laboratory offering testing,
information and related services to physician offices, clinics,
hospitals, employers and governmental units. We believe that we are the
fourth largest full-service laboratory in the United States and the
largest independent regional laboratory in the Northeastern market.
BioReference offers a comprehensive list of laboratory testing services
utilized by healthcare providers in the detection, diagnosis,
evaluation, monitoring and treatment of diseases. BioReference primarily
focuses on esoteric testing, molecular diagnostics, anatomical
pathology, women’s health and correctional health care.
Caution Concerning Forward-Looking Statements
Statements included in this release that are not historical in nature
are intended to be, and are hereby identified as, “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by
words such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates," "will" or words of similar meaning and include,
but are not limited to, statements about the expected future business
and financial performance of Bio-Reference Laboratories, Inc. and its
subsidiaries. Such statements involve known and unknown risks and
uncertainties that may cause the Company’s actual results in future
periods to be materially different from any future performance suggested
herein. Risks and uncertainties that may affect the future results of
the Company include, but are not limited to, adverse results from
failure to comply with applicable laws and regulations governing our
business or government investigations, lawsuits or private actions, the
competitive environment, changes in government regulations, changing
relationships with customers, payers, suppliers and strategic partners
and other risks and uncertainties detailed from time to time in our
filings with the Securities and Exchange Commission. We undertake no
obligation to publicly update or review any forward-looking information,
whether as a result of new information, future developments or otherwise.
Source: Bio-Reference Laboratories, Inc.
Bio-Reference Laboratories, Inc.
Tara Mackay, 201-791-2600